| Name | Title | Contact Details |
|---|
BillionToOne is a precision diagnostics company with the mission to make molecular diagnostics more accurate, efficient, and accessible. Our proprietary molecular counting platform can accurately count DNA molecules at the single-count level to help improve disease detection.
Karius is a life sciences company focused on generating genomic insights for infectious diseases with a non-invasive blood test that helps clinicians make rapid treatment decisions. By mapping each patient`s microbial landscape from a single blood draw, Karius moves closer to a vision of a world where infectious disease is no longer a major threat to human health.
Talis is developing a new class of diagnostic platform to enable rapid, high-complexity testing across a wide range of healthcare settings.
SIGA Technologies is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
GenSight Biologics is is a clinical-stage biotechnology company discovering and developing novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. GenSight Biologics` pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics for retinitis pigmentosa, to help preserve or restore vision in patients suffering from severe degenerative retinal diseases. GenSight Biologics` lead product candidate, GS010, is in Phase III trials in Leber`s Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease that leads to irreversible low vision and legal blindness in teens and young adults. Using its gene therapy-based approach, GenSight Biologics` product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery.